APA (7th ed.) Citation

Loibl, S., & Schneeweiss, A. (2016). A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4673 (durvalumab) to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (GeparNuevo). Annals of oncology, 27, . https://doi.org/10.1093/annonc/mdw364.77

Chicago Style (17th ed.) Citation

Loibl, Sibylle, and Andreas Schneeweiss. "A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4673 (durvalumab) to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)." Annals of Oncology 27 (2016). https://doi.org/10.1093/annonc/mdw364.77.

MLA (9th ed.) Citation

Loibl, Sibylle, and Andreas Schneeweiss. "A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4673 (durvalumab) to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)." Annals of Oncology, vol. 27, 2016, https://doi.org/10.1093/annonc/mdw364.77.